NEW YORK (AP) – Watson Pharmaceuticals Inc. said on July 11 it licensed a potential treatment for overactive bladder from Antares Pharma Inc.
Watson will make a payment to Antares if the Food and Drug Administration approves the drug, which Antares has been developing under the name Anturol. Watson will also market the drug and make payments to Antares based on sales.
Antares’ product is a gel version of oxybutynin, a drug that is already used as a treatment for overactive bladder. The FDA is scheduled to make a decision on Anturol by Dec. 8.
The companies did not disclose specific terms of their agreement.
The Associated Press
Filed Under: Drug Discovery